76 per cent of participants in MDMA-assisted therapy for PTSD have responded well
This Phase Two trial was undertaken in Colorado
MDMA being used to treat post-traumatic stress disorder (PTSD) has turned out to be quite successful.
It's reported that 76 per cent of the 28 involved in a Phase Two trial undertaken in Colorado didn't meet the clinical diagnostic criteria of PTSD 12 months on from receiving treatment.
Treatment consisted of a pair of two day-long MDMA-led sessions with integrative therapy sessions. A third MDMA treatment session was also held.
The Multidisciplinary Association for Psychedelic Studies (MAPS) are carrying out the trials. Phase Three kicked off in September this year, involving between 200 and 300 people in the United States, Canada and Israel. These are expected to go on for two years.
It's hoped the US Food and Drug Administration will approve MDMA's use for PTSD treatment by 2021.
[Via: New Atlas]
[Photo: MDMA Team]
Dave Turner is Mixmag's Digital News Editor, follow him on Twitter
Mixmag will use the information you provide to send you the Mixmag newsletter using Mailchimp as our marketing platform. You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us. By clicking sign me up you agree that we may process your information in accordance with our privacy policy. Learn more about Mailchimp's privacy practices here.
